ImmuneOncia Therapeutics has entered a manufacturing agreement with Swiss contract drugmaker Lonza to support late‑stage clinical production of Danburstotug, an experimental monoclonal antibody targeting PD‑L1 for relapsed or refractory NK/T‑cell lymphoma. Under the deal, Lonza will produce drug substance at its Slough, U.K., facility, while drug‑product development and clinical manufacturing will occur at sites in Basel and Stein, Switzerland. The South Korea–based biotech said it is leverag...